Trevena Company Profile (NASDAQ:TRVN)

About Trevena (NASDAQ:TRVN)

Trevena logoTrevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TRVN
  • CUSIP: N/A
  • Web:
  • Market Cap: $109.24 million
  • Outstanding Shares: 59,696,000
Average Prices:
  • 50 Day Moving Avg: $2.43
  • 200 Day Moving Avg: $2.69
  • 52 Week Range: $1.57 - $8.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.18
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.94 per share
  • Price / Book: 1.77
  • EBITDA: ($106,040,000.00)
  • Return on Equity: -145.70%
  • Return on Assets: -99.23%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 7.15%
  • Quick Ratio: 7.15%
  • Average Volume: 568,392 shs.
  • Beta: -0.5
  • Short Ratio: 7.32

Frequently Asked Questions for Trevena (NASDAQ:TRVN)

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.35) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.35). View Trevena's Earnings History.

When will Trevena make its next earnings announcement?

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Trevena.

Where is Trevena's stock going? Where will Trevena's stock price be in 2017?

12 brokers have issued 1-year price targets for Trevena's shares. Their predictions range from $2.50 to $16.00. On average, they expect Trevena's share price to reach $10.21 in the next twelve months. View Analyst Ratings for Trevena.

What are analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:

  • 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (10/18/2017)
  • 2. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
  • 3. Cowen and Company analysts commented, "TRVN reported 4Q16 results." (3/22/2017)
  • 4. HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
  • 5. Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)

Who are some of Trevena's key competitors?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:

  • Leon O. Moulder Jr., Independent Chairman of the Board
  • Maxine Gowen Ph.D., President, Chief Executive Officer, Director
  • Roberto E. Cuca, Chief Financial Officer, Senior Vice President
  • Michael W. Lark Ph.D., Senior Vice President - Research, Chief Scientific Officer
  • John M. Limongelli Esq., Senior Vice President, General Counsel, Corporate Secretary
  • Carrie L. Bourdow, Senior Vice President, Chief Commercial Officer
  • Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning
  • David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer
  • Michael R. Dougherty, Independent Director
  • Adam M. Koppel M.D. Ph.D., Independent Director

How do I buy Trevena stock?

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of Trevena stock can currently be purchased for approximately $1.66.

MarketBeat Community Rating for Trevena (NASDAQ TRVN)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trevena (NASDAQ:TRVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $10.21 (514.96% upside)
Consensus Price Target History for Trevena (NASDAQ:TRVN)
Price Target History for Trevena (NASDAQ:TRVN)
Analysts' Ratings History for Trevena (NASDAQ:TRVN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Barclays PLCDowngradeOverweight -> Equal Weight$15.00 -> $2.50N/AView Rating Details
10/12/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$5.00N/AView Rating Details
10/12/2017HC WainwrightLower Price TargetBuy -> Buy$8.00 -> $7.00N/AView Rating Details
8/4/2017Cowen and CompanyReiterated RatingBuy$10.00MediumView Rating Details
5/15/2017Needham & Company LLCBoost Price TargetBuy$9.00 -> $11.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
4/17/2017AegisReiterated RatingBuy$14.00LowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$8.00HighView Rating Details
2/16/2017Jefferies Group LLCReiterated RatingBuy$11.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$15.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00N/AView Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00N/AView Rating Details
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Trevena (NASDAQ:TRVN)
Earnings by Quarter for Trevena (NASDAQ:TRVN)
Earnings History by Quarter for Trevena (NASDAQ TRVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.33)N/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.35)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.55)($0.36)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.62)($0.67)$0.48 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.40)($0.57)$1.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)$1.93 million$1.88 millionViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)$1.80 million$1.88 millionViewN/AView Earnings Details
8/11/2015Q215($0.37)($0.28)$1.30 million$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)$10.00 million$0.63 millionViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Trevena (NASDAQ:TRVN)
2017 EPS Consensus Estimate: ($1.64)
2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.38)($0.48)
Q2 20174($0.54)($0.36)($0.43)
Q3 20174($0.50)($0.21)($0.37)
Q4 20174($0.54)($0.17)($0.36)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)


Dividend History for Trevena (NASDAQ:TRVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Trevena (NASDAQ:TRVN)
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 60.09%
Insider Trades by Quarter for Trevena (NASDAQ:TRVN)
Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)
Insider Trades by Quarter for Trevena (NASDAQ:TRVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.00View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.00View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Trevena (NASDAQ:TRVN)
Latest Headlines for Trevena (NASDAQ:TRVN)
DateHeadline logoWhy I See Trevena Going To Zero - Seeking Alpha - October 18 at 9:44 AM logoHC Wainwright Lowers Trevena, Inc. (TRVN) Price Target to $7.00 - October 15 at 7:56 AM logoOppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target - October 12 at 6:26 PM logoAfter-Hours Movers 10/11: (ARDX) (BW) (SIGM) Higher; (JILL) (TRVN) (PTGX) Lower (more...) - October 11 at 9:12 PM logoChesco biopharm firm cuts 21 jobs as part of restructuring - October 11 at 9:12 PM logoInteresting TRVN Call Options For November 17th - October 11 at 4:08 PM logoTrevena Announces Restructuring to Focus Resources on Commercial Strategy - October 11 at 4:08 PM logoTrevena, Inc. (TRVN) Receives Consensus Rating of "Buy" from Brokerages - October 11 at 4:50 AM logo-$0.31 EPS Expected for Trevena, Inc. (TRVN) This Quarter - October 4 at 2:36 PM logoTrevena To Present at the Ladenburg Thalmann 3rd Annual 2017 Healthcare Conference - GlobeNewswire (press release) - September 24 at 8:31 AM logoFinancial Comparison: Flex Pharma (FLKS) vs. Trevena (TRVN) - September 19 at 2:48 PM logoTrevena, Inc. (TRVN) Given Consensus Recommendation of "Buy" by Analysts - September 16 at 4:42 AM logoTrevena (TRVN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 11:40 AM logoTrevena Announces Presentations during PAINWeek® 2017 - GlobeNewswire (press release) - September 8 at 3:29 PM logoTrevena Announces Presentations during PAINWeek® 2017 - September 8 at 9:32 AM logoTrevena to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - September 6 at 9:26 AM logoTrevena, Inc. (TRVN) Earns "Buy" Rating from Cowen and Company - August 4 at 1:48 PM logoTrevena, Inc. (TRVN) Posts Earnings Results, Hits Expectations - August 3 at 9:21 PM logoTrevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 3 at 8:08 AM logoTrevena reports 2Q loss - August 3 at 8:08 AM logoTrevena, Inc. (NASDAQ:TRVN) Given Consensus Rating of "Buy" by Brokerages - July 28 at 9:39 AM logoTrevena, Inc. (TRVN) Scheduled to Post Earnings on Wednesday - July 26 at 7:49 AM logoTrevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release) - July 22 at 9:53 AM logoTrevena To Host 2017 Analyst Day and Announce Results of ATHENA Open Label Safety Study of OLINVO - July 21 at 8:04 AM logoTrevena, Inc. (TRVN) Expected to Post Earnings of -$0.36 Per Share - July 20 at 6:24 PM logoTrevena to Host Analyst Day on July 20, 2017 - GlobeNewswire (press release) - July 14 at 9:21 PM logoTrevena to Host Analyst Day on July 20, 2017 - July 13 at 10:43 AM logoThis $3 Biotech Stock Is Making an 11% Move Thursday - July 13 at 10:43 AM logoStemline Therapeutics (STML) vs. Trevena (TRVN) Head to Head Survey - July 4 at 8:16 PM logoTrevena, Inc. (TRVN) Receives Average Recommendation of "Buy" from Analysts - July 3 at 9:56 AM logoTrevena (TRVN) Says Two Posters at ASRA Highlight Positive Phase 3 Data Comparing OLINVO with Intravenous Morphine - April 7 at 6:08 PM logoBuying Trevena Inc. Could Be A Huge Upside Trade - March 21 at 8:08 PM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trevena, Inc. (TRVN) - PR Newswire (press release) - March 15 at 10:30 PM logoTrevena to Present at the 2017 Barclays Global Healthcare Conference - GlobeNewswire (press release) - March 11 at 8:07 AM logoTrevena Reports Full Year 2016 Earnings - March 9 at 3:11 AM logoTREVENA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 9 at 3:11 AM logoQ4 2016 Trevena Inc Earnings Release - Before Market Open - March 9 at 3:11 AM logoTrevena reports 4Q loss - March 9 at 3:11 AM logoTrevena Inc Earnings Call scheduled for 8:00 am ET today - March 9 at 3:11 AM logoTREVENA INC Files SEC form 8-K, Change in Directors or Principal Officers - March 4 at 2:14 AM logoFirst Week of April 21st Options Trading For Trevena - - February 23 at 2:21 AM logoFCX, TRVN and UL stock used more than their fair share of red ink on Tuesday - February 22 at 10:27 AM logoTrevena's 30% Plunge, Explained - February 21 at 4:38 PM logoTrevena's stock drops 30% despite positive study results for pain drug - February 21 at 4:38 PM logoTrevena (TRVN) Says Two Phase 3 Studies of Oliceridine Achieved Primary Endpoint - February 21 at 4:38 PM logoTrevena Plunges 34% On Painkiller Results (TRVN) - February 21 at 4:38 PM logoTREVENA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - February 21 at 4:38 PM logoTrevena's painkiller succeeds in two late-stage studies - February 21 at 4:38 PM logoTrevena Makes Case for Better Post-Surgical Opioid with New Study Data - February 21 at 4:38 PM logoSarepta Leads Biotech Movers on Voucher Deal News - February 21 at 4:38 PM



Trevena (TRVN) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.